SEC Form 4 · accession 0001144204-18-012825
ANI PHARMACEUTICALS INC · ANIP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert W Schrepfer
Officer — SVP - New Bus Dev & Spec Sales
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001023024
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2018 | M | 18,750 | $28.76 | A | 41,590 | D | |
| Common StockF1 | Mar 1, 2018 | S | 5,498 | $60.33 | D | 36,092 | D | |
| Common StockF2 | Mar 1, 2018 | S | 10,800 | $61.64 | D | 25,292 | D | |
| Common StockF3 | Mar 1, 2018 | S | 11,954 | $62.25 | D | 13,338 | D | |
| Common Stock | Mar 1, 2018 | S | 400 | $63.07 | D | 12,938 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4 | $28.76 | Mar 1, 2018 | M | 18,750 | D | — | Aug 19, 2024 | Common Stock | 18,750 | 6,250 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $61.00 to $61.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $62.00 to $62.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date of the options was August 20, 2014.